Akari Therapeutics PLC (AKTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Akari Therapeutics PLC (AKTX) has a cash flow conversion efficiency ratio of -0.107x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.04 Million) by net assets ($28.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AKTX net asset quality score to measure how much of total assets are equity-financed.
Akari Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Akari Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AKTX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Akari Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akari Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JE Cleantech Holdings Ltd
NASDAQ:JCSE
|
0.001x |
|
Yoshiharu Global Co.
NASDAQ:YOSH
|
-0.192x |
|
Manhattan Corporation Limited
F:32U
|
-0.016x |
|
Siamraj Public Company Limited
BK:SR
|
0.026x |
|
Pacific Nickel Mines Ltd
AU:PNM
|
-1.186x |
|
Garibaldi Resources Corp.
V:GGI
|
-0.004x |
|
Tyranna Resources Ltd
AU:TYX
|
-0.403x |
|
Protektor S.A.
WAR:PRT
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Akari Therapeutics PLC (2010–2025)
The table below shows the annual cash flow conversion efficiency of Akari Therapeutics PLC from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see AKTX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $28.33 Million | $-10.57 Million | -0.373x | +33.93% |
| 2024-12-31 | $22.23 Million | $-12.55 Million | -0.565x | -100.79% |
| 2023-12-31 | $-229.00K | $-16.43 Million | 71.755x | +697.63% |
| 2022-12-31 | $1.79 Million | $-21.50 Million | -12.007x | -253.87% |
| 2021-12-31 | $5.55 Million | $-18.85 Million | -3.393x | -87.85% |
| 2020-12-31 | $9.38 Million | $-16.95 Million | -1.806x | +46.36% |
| 2019-12-31 | $3.84 Million | $-12.92 Million | -3.368x | -99.88% |
| 2018-12-31 | $13.38 Million | $-22.54 Million | -1.685x | -6.53% |
| 2017-12-31 | $19.98 Million | $-31.60 Million | -1.582x | -119.04% |
| 2016-12-31 | $34.10 Million | $-24.62 Million | -0.722x | -608.46% |
| 2015-12-31 | $48.72 Million | $-4.97 Million | -0.102x | +94.77% |
| 2014-12-31 | $4.85 Million | $-9.46 Million | -1.950x | -107.97% |
| 2013-12-31 | $5.81 Million | $-5.45 Million | -0.937x | -247.59% |
| 2012-12-31 | $-3.36 Million | $-2.13 Million | 0.635x | +56.57% |
| 2011-12-31 | $-2.48 Million | $-1.01 Million | 0.406x | +124.84% |
| 2010-12-31 | $-2.03 Million | $-366.00K | 0.180x | -- |
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat s… Read more